Litcius/Paper detail

Multilayer spectrum of intratumoral heterogeneity in basal bladder cancer

Nanor Sirab, Damien Drubay, Pascale Maillé, Tatiana Popova, Carine Ngo, David Gentien, Anissa Moktefi, Pascale Soyeux-Porte, Romain Pelletier, Cécile Réyès, Émilie Henry, Damien Pouessel, Dimitri Vordos, Thierry Lebrét, Aurélien de Reyniès, Xavier Paolettí, François Radvanyi, Yves Allory

2021The Journal of Pathology20 citationsDOI

Abstract

Basal/squamous (Ba/Sq) subtype represents an intrinsic and robust group in the consensus molecular classification of muscle-invasive bladder cancer (MIBC), with poor outcome and controversial chemosensitivity. We aimed to investigate the spectrum of intratumor heterogeneity (ITH) in the Ba/Sq subtype. First, we validated a 29-gene NanoString CodeSet to predict the Ba/Sq subtype for FFPE samples. We identified heterogeneous Ba/Sq tumors in a series of 331 MIBC FFPE samples using dual GATA3/KRT5/6 immunohistochemistry (IHC). Heterogeneous regions with distinct immunostaining patterns were studied separately for gene expression using the 29-gene CodeSet, for mutations by targeted next-generation sequencing, and for copy number alteration (CNA) by microarray hybridization. Among 83 Ba/Sq tumors identified by GATA3/KRT5/6 dual staining, 19 tumors showed heterogeneity at the IHC level. In one third of the 19 cases, regions from the same tumor were classified in different distinct molecular subtypes. The mutational and CNA profiles confirmed the same clonal origin for IHC heterogeneous regions with possible subclonal evolution. Overall, two patterns of intratumoral heterogeneity (ITH) were observed in Ba/Sq tumors: low ITH (regions with distinct immunostaining, but common molecular subtype and shared CNA) or high ITH (regions with distinct immunostaining, molecular subtype, and CNA). These results showed multilayer heterogeneity in Ba/Sq MIBC. In view of personalized medicine, this heterogeneity adds complexity and should be taken into account for sampling procedures used for diagnosis and treatment choice. © 2021 The Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Topics & Concepts

ImmunostainingBiologyImmunohistochemistryBladder cancerKRASGenetic heterogeneityPathologyGATA3CancerGeneMutationMedicinePhenotypeGeneticsTranscription factorBladder and Urothelial Cancer TreatmentsUrinary and Genital Oncology StudiesEpigenetics and DNA Methylation
Multilayer spectrum of intratumoral heterogeneity in basal bladder cancer | Litcius